News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Euro News, Articles and Videos with Contenting
1. "EU Proposes New Rules on Digital Tax to Make Tech Giants Pay Their Share" - This article from Reuters discusses how the European Union's executive branch proposed new rules for digital taxation to ensure tech giants pay their fair share of taxes. The new rules are set to impact companies like Amazon, Apple, Facebook, and Google. 2. "Germany, France and Italy Sign Pact to Tax Digital Giants" - This article from the New York Times discusses how Germany, France, and Italy have signed a pact to tax digital companies such as Amazon, Apple, Facebook, and Google. The agreement is the first major step in the European Union's effort to tax tech giants. 3. "EU's New Digital Tax Plan: What You Need to Know" - This video from Euronews explains the European Union's new digital tax plan and how it will affect tech giants such as Amazon, Apple, Facebook, and Google. The video also explains the different aspects of the plan and how it will be implemented.
Award Of Rights Under The Company’s SARs Scheme - ForexTV
Vast Resources plc / Ticker: VAST / Index: AIM / Sector: Mining 7 July 2025 Vast Resources plc(“Vast” or the “Company”) Award of rights to employees and consultants under theCompany’s Share Appreciation Rights (“SARs”) scheme Vast Resources plc, the AIM-listed mining company, announces the grant of certain awards (the “Awards”) under the Company’s Share Appreciation Rights scheme (the “Scheme”). The Scheme was established in June 2015 to incentivise directors, management, employees and consultants of the Company. The basis of the Scheme The basis of the Scheme is to grant a fixed number of SARs to participants, whereby each SAR gives the holder the right, at the discretion of the Company, to either receive an ordinary share of 0.1p in Vast (each an “Ordinary Share” and together the “Ordinary Shares”) based on the relevant grant price of the SARs (the “Grant Price”), or to receive cash equal to the difference between the Grant Price and the volume weighted average price of the Company’s Ordinary Shares on the date of exercise of the SAR. Subject to any condition imposed in relation to any particular Award, a SAR may be exercised at any time from the date of issue until the date of its expiry. The Awards The aggregate Awards to employees and consultants represent a total of 57,500,000 SARs, with such SARs expiring on 31 March 2028. The employees and consultants to whom the Awards are being made, and who do not include any directors of the Company, have over the past several months all agreed to accept significant deferment of remuneration or fees due to them pending the release of the Company’s historical diamond parcel. As a consequence, the Grant Price applicable to the Awards has been agreed by the Company’s board of directors to be 0.142p, being the VWAP of the Ordinary Shares the day following the announcement of the release of the historical diamond parcel, instead of a price equal to the 6 month VWAP of an Ordinary Share immediately preceding the grant of a SAR, which would otherwise be the Grant Price under the rules of the Scheme. The Company is also reviewing incentives to executive directors and other senior personnel, with a view to making further SARs awards in due course. Such SARs are expected to be on broadly similar terms and represent a maximum entitlement to Ordinary Shares representing, in aggregate, approximately 3.7 per cent. of the Company’s currently issued share capital. **ENDS** For further information, please visit the Company’s website at www.vastplc.com or contact: Vast Resources plcAndrew Prelea (CEO)+44 (0) 20 7846 0974 Strand Hanson Limited – Nominated & Financial AdviserJames Spinney / James Bellman+44 (0) 207 409 3494 Shore Capital Stockbrokers Limited – Joint BrokerToby Gibbs / James Thomas (Corporate Advisory)+44 (0) 20 7408 4050 Axis Capital Markets Limited – Joint BrokerRichard Hutchinson+44 (0) 20 3206 0320 St Brides Partners LimitedSusie Geliherhttp://www.stbridespartners.co.uk/+44 (0) 20 7236 1177 ABOUT VAST RESOURCES Vast Resources plc is a United Kingdom AIM quoted mining company with mines and projects in Romania, Tajikistan, and Zimbabwe. In Romania, the Company is focused on the rapid advancement of high-quality projects by recommencing production at previously producing mines. The Company's Romanian portfolio includes 100% interest in Vast Baita Plai SA which owns 100% of the producing Baita Plai Polymetallic Mine, located in the Apuseni Mountains, Transylvania, an area which hosts Romania's largest polymetallic mines. The mine has a JORC compliant Reserve & Resource Report which underpins the initial mine production life of approximately 3-4 years with an in-situ total mineral resource of 15,695 tonnes copper equivalent with a further 1.8M-3M tonnes exploration target. The Company is now working on confirming an enlarged exploration target of up to 5.8M tonnes. The Company also owns the Manaila Polymetallic Mine in Romania, which the Company is looking to bring back into production following a period of care and maintenance. The Company has also been granted the Manaila Carlibaba Extended Exploitation Licence that will allow the Company to re-examine the exploitation of the mineral resources within the larger Manaila Carlibaba licence area. The Company retains a continued presence in Zimbabwe. The Company is re-engaging its future investment strategy in Zimbabwe and has commenced discussions with further mining concessions in-country alongside its wider portfolio. Vast has an interest in a joint venture company which provides exposure to a near term revenue opportunity from the Takob Mine processing facility in Tajikistan. The Takob Mine opportunity, which is 100% financed, will provide Vast with a 12.25 percent royalty over all sales of non-ferrous concentrate and any other metals produced. Also in Tajikistan, Vast has been contracted to develop and manage the Aprelevka gold mines on behalf of its owner Gulf International Minerals Ltd (“Gulf”) under which Vast is entitled, inter alia, to 10% of the earnings that Gulf receives from its 49% interest in Aprelevka in joint venture with the government of Tajikistan. Aprelevka holds four active operational mining licences located along the Tien Shan Belt that extends through Central Asia, currently producing approximately 11,600oz of gold and 116,000 oz of silver per annum. It is the intention of the Company to assist in increasing Aprelevka’s production from these four mines closer to the historical peak production rates of approximately 27,000oz of gold and 250,000oz of silver per year from the operational mines. The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019.
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers - ForexTV
First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, July 7, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the first dosing in its Phase 1 clinical study investigating the company’s Factor H (CPV-104) program in C3-Glomerulopathy (C3G). In the first part of the clinical study, Eleva is investigating single-ascending doses of CPV-104 in healthy volunteers. “Today’s news marks our second proprietary program advancing into clinical trials, which is a great achievement from an organizational standpoint,” commented Björn Cochlovius, Ph.D., Chief Executive Officer of Eleva. “Our Factor H biological therapy platform continues to evolve, gaining visibility among clinicians and potential partners alike. We will continue to add value to this program in C3G as our initial focus, dry AMD as a second indication, and potentially several others down the road, while creating the best infrastructure for its successful clinical development.” “We are thrilled to advance our Factor H molecule into a first-in-human study to evaluate the safety and tolerability and pharmacokinetics for further clinical studies. I like to thank all team members at Eleva and our clinical partners for their continued efforts and commitment to meet this milestone,” commented Dr. Martin Bauer, Chief Medical Officer of Eleva. C3G represents a rare renal disease caused by the abnormal regulation of the complement system, particularly the alternative pathway of the complement cascade, a central part of the body’s immune defense. Naturally occurring complement regulators such as Factor H offer a therapeutic approach to help restore balance within the complement system and have shown therapeutic potential in a range of indications. Preclinical data sets were recently published in Frontiers in Immunology and underscored Factor H (CPV-104)’s ability to act as a functional analogue of human Factor H, support normalization of serum C3 levels and lead to a rapid degradation of C3 deposits in the kidney. The program has received the Orphan Drug Designation in the European Union for C3G and is also being pursued by Eleva in dry AMD as a second indication. ABOUT ELEVAEleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva’s disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that other platforms cannot achieve. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company’s aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease. MEDIA CONTACTS Fabienne ZeitterDirector Marketingpr@elevabiologics.comPhone: +49 761 470 99 0 Valency CommunicationsMario Brkuljmbrkulj@valencycomms.euPhone: +49 160 9352 9951 INVESTOR CONTACT Cohesion BureauGiovanni Ca’ Zorzigiovanni.cazorzi@cohesionbureau.comPhone: +33 7 84 67 07 27 Attachment 250707_Eleva_1st_Dosing_FactorH_ENG
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe - ForexTV
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But without urgent policy leadership and better regulation, Europe risks becoming the world’s best lab for solutions that scale elsewhere. Copenhagen, Denmark – 7 July 2025: Europe is on the verge of a job and growth boom if biosolutions are prioritized and supported by the right policy framework. That is the conclusion in a new report by Amsterdam Data Collective (ADC), which for the first time quantifies the economic potential of the biosolutions sector in Europe, individual member states and globally. According to the report, the biosolutions industry could create more than 600,000 direct and indirect jobs in Europe by 2035—nearly the equivalent of the entire population of Luxembourg. In just a decade, the total economic gain could reach EUR 133 billion, with EUR 46 billion in direct value - or the same as the combined annual contributions from France, Italy and Spain to the EU budget. In addition, the analysis shows that each job in biosolutions generates nearly three additional jobs across other industries in Europe. As countries worldwide ramp up policy support and investments in biosolutions, Europe has a unique position to lead the charge and strengthen its competitiveness. Industry leaders are calling for immediate action to ensure that Europe gets the right political framework to fully realize its potential. “Europe has world-class companies, cutting-edge innovations, and determined leaders. But if we are to realize the enormous potential of biosolutions to drive economic growth and resilience, we need active leadership and fit-for-purpose regulation. That will also create a more attractive investment environment and thereby a stronger ecosystem where the next wave of biosolutions companies can thrive and scale,” says Johan Weimann, Regional President Europe at Novonesis. To stay ahead, Europe must act now As the global race for leadership in biosolutions intensifies, speed is becoming a decisive currency. Today, approval for a novel protein can take up to three years in the EU. This is far longer than in faster-moving markets like Singapore, where it takes just four to six months. In the US and Brazil, new biopesticides are typically approved within two to three years—compared to six to eight years in the EU. Brazil, too, has introduced a new bioinput law to fast-track commercial use of biosolutions—making it easier to adopt more sustainable practices across agriculture, livestock, aquaculture, and forestry. As countries move quickly, backing innovation with significant investments and streamlined regulatory processes, Europe risks becoming the world’s best lab for solutions that scale elsewhere unless better regulation creates faster pathways from lab to market. “Biosolutions create value far beyond their own sector. When we know that each job leads to nearly three more, we’re looking at a multiplier effect that Europe can’t afford to ignore. It is a wake-up call at a decisive moment. If we want to retain, scale and foster the future biosolutions leaders in Europe, we need much faster approval processes and a bold and broad EU Biotech Act,” says Sofie Carsten Nielsen, Director of the European Biosolutions Coalition. Biosolutions could transform the global economyThe report estimates that biosolutions could inject over EUR 877 billion into the global economy and generate more than five million jobs by 2035. These figures highlight the urgent need for Europe to capitalize on this momentum. “Europe stands at a critical juncture facing rising global competition. With the right policies, biosolutions can drive Europe’s competitiveness and green transition, offering biological answers to the defining challenges of our time. With the potential to generate over 600,000 European jobs by 2035, biosolutions are emerging as a sector that rivals traditional industries in scale and impact. The “Value of Biosolutions” report tells a story that should capture the attention of every policymaker, business leader, and citizen across Europe," says Morten Løkkegaard, Member of the European Parliament, Vice-President Renew Europe and Chairman of the Parliamentary Interest Group on Biosolutions. “Biosolutions is a growing business with enormous potential in the industrial bioeconomy. The report clearly shows that the sector is experiencing global growth. At the same time, it serves as an important guidepost for the key challenges and opportunities facing decision-makers and investors,” adds Christine Lang, Co-Chair of the International Advisory Council on Global Bioeconomy. Biosolutions play a crucial role in solving some of the world’s most urgent crises and pave the way for new business models. Using microbes, enzymes, and other proteins as building blocks, biosolutions help businesses reduce waste, save energy and water, cut dependence on fossil resources, and develop innovative and profitable products. Biosolutions are already used across more than 30 industries, from preventive health and industrial applications to agriculture and food production. Download the report and access data across EU Member States and the UK: ‘The Value of Biosolutions’ About the ‘The Value of Biososlutions’ The report is developed by Amsterdam Data Collective (ADC) and commissioned by Novonesis. The analyses in the report were carried out by ADC with input from experts in the biosolutions field including DI Biosolutions, the European Biosolutions Coalition, the International Advisory Council on Global Bioeconomy, Novonesis, and the World Economic Forum Bioeconomy Initiative and the support of policy knowledge partners Dragoman and Szpirt &Co. Facts (ADC, 2025) EU(2024) 278,000 direct and indirect jobsEUR 60 billion in economic impact, with EUR 24billion in direct value creation from the industry (2035) - provided the right policy framework is in place EUR 133 billion in economic impact, with more than EUR 46 billion in direct value creation from the industryUp to 604,000 direct and indirect jobsIn Europe, each job in biosolutions creates 2.9 additional jobs Globally(2024) 1.85 million direct and indirect jobsEUR 313 billion in economic footprint, with EUR 118 billion in direct value creation from the industry (2035) - provided the right policy framework is in place Up to EUR 877 billion in economic footprint, with EUR 291 billion in direct value creation from the industryOver 5 million direct and indirect jobs Globally, each job in biosolutions creates 2.4 additional jobs Contact Jens Gamborg, Head of External Communications, Novonesis: +45 3077 7182 / media-relations@novonesis.com Attachment VoB_Executive Summary_EU_FINAL (1)
Capgemini to acquire WNS to create a global leader in Agentic AI-powered Intelligent Operations - ForexTV
Media relations:Victoire GruxTel.: +33 6 04 52 16 55victoire.grux@capgemini.com Investor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com Capgemini to acquire WNS to create a global leader in Agentic AI-powered Intelligent Operations Creation of a leader in Intelligent Operations to capture enterprise investment in Agentic AI to transform their end-to-end business processes Acquisition of a leading player in Digital BPS (Business Process Services) to combine capabilities and scale to address the strategic opportunity driven by Agentic AI Transaction immediately accretive to Capgemini’s revenue growth and operating marginExpected accretion to Capgemini’s normalized EPS of 4% before synergies in 2026, and 7% post-synergies in 2027Definitive transaction agreement entered into pursuant to which Capgemini will acquire WNS for a cash consideration of 76.50 USD per shareTransaction unanimously approved by the board of directors of both companies and expected to close by the end of the year Paris, July 7, 2025 – Capgemini (Euronext Paris: CAP), a global business and technology transformation partner, and WNS (NYSE: WNS), a leading digital-led business transformation and services company, today announced that they have entered into a definitive transaction agreement pursuant to which Capgemini will acquire WNS for a cash consideration of 76.50 USD per WNS share, which represents a premium of 28% to the last 90-day average1 share price, of 27% to the last 30-day average1 share price and a premium of 17% to the last closing share price on July 3, 2025. The total cash consideration will amount to $3.3 billion, excluding WNS net financial debt2. The transaction will be accretive to Capgemini’s normalized EPS by 4% before synergies in 2026 and 7% post synergies in 2027. The transaction has been unanimously approved by both Capgemini’s and WNS’ Boards of Directors. “Enterprises are rapidly adopting Generative AI and Agentic AI to transform their operations end-to-end. Business Process Services will be the showcase for Agentic AI. Capgemini’s acquisition of WNS will provide the Group with the scale and vertical sector expertise to capture that rapidly emerging strategic opportunity created by the paradigm shift from traditional BPS to Agentic AI-powered Intelligent Operations,” comments Aiman Ezzat, Chief Executive Officer of Capgemini. “Together we will create a leader in Intelligent Operations, uniquely positioned to support organizations in their AI-powered business process transformation, blending the critical capabilities needed from consulting, technology and platforms to deep process and industry expertise. This will address the client needs for Agentic AI-driven process transformation to deliver efficiency and agility through hyper-automation while achieving superior business outcomes. WNS brings to the Group its high growth, margin accretive and resilient Digital Business Process Services, which is the springboard to Intelligent Operations, while further increasing our exposure to the US market. Immediate cross-selling opportunities will be unlocked through the integration of our complementary offerings and clients. I am looking forward to welcoming the WNS global team to Capgemini.” “As a recognized leader in the Digital Business Process Services space, we see the next wave of transformation being driven by intelligent, domain-centric operations that unlock strategic value for our clients. Organizations that have already digitized are now seeking to reimagine their operating models by embedding AI at the core—shifting from automation to autonomy,” said Keshav R. Murugesh, Chief Executive Officer of WNS. “By combining our deep domain and process expertise with Capgemini’s global reach, cutting-edge Gen AI and Agentic AI capabilities, a robust partner ecosystem, and advanced technology platforms, we are creating a powerful proposition that accelerates enterprise reinvention. WNS’ complementary portfolio of horizontal and industry-specific solutions will significantly enhance Capgemini’s rapidly growing Business Services footprint, enabling next-generation, data-driven operations across sectors. Just as importantly, our shared values, cultural alignment, and complementary client relationships ensure a seamless integration—unlocking exciting opportunities for innovation, co-creation, and growth across all stakeholder groups.” “WNS and Capgemini share a bold, future-focused vision for Intelligent Operations. I’m confident that Capgemini is the ideal partner at the right time in WNS’ journey to extend our capabilities, accelerate innovation, and establish a leadership position in this rapidly evolving market,” said Timothy L. Main, Chairman of WNS Board of Directors. “This marks a pivotal chapter in WNS’ growth—enhancing the resilience and agility of our clients through advanced AI-driven solutions, creating sustained value for our investors, and opening up new avenues for our employees to thrive within a global technology powerhouse.” WNS, a leader in the resilient high-growth and margin accretive Digital BPS market WNS is a leading and trusted business transformation and services partner that uniquely blends deep industry knowledge with business process management, technology, analytics and AI expertise to create market differentiation for clients. With digital-led transformation solutions deployed to clients across 8 industries where it deploys its highly automated platforms to deliver stronger business outcomes, WNS is a leader in Digital Business Process Services (BPS). This operating model enables strategic engagements that are critical to clients’ daily operations materialized in long-term contracts with recurring revenues streams. Through an expanded ecosystem of partners and network of delivery centers, WNS serves a large portfolio of blue-chip clients, such as3 United Airlines, Aviva, M&T Bank, Centrica and McCain Foods. The high-quality business model of WNS, supported by non-linear pricing models and superior profitability has driven a c.+9% constant currency revenue growth on average over the last 3 fiscal years4, to reach $1,266 million of revenue5 in fiscal year 20254 with an 18.7%6 operating margin. Global organizations are in constant need of strategic partners to support their transformation to enhance efficiency and accelerate growth. This continues to be a key driver of the Digital BPS market and WNS targets revenue growth of +7% to +11% for FY2026. Immediate unlocking of value This transaction will position Capgemini as a leader in Digital BPS blending horizontal and vertical process expertise, with a global footprint. With combined revenues of €1.9 billion in 2024 in Digital BPS, this will strengthen Capgemini’s ability to accompany clients on their business and technology transformation journeys. The mix of WNS and Capgemini’s complementary offerings and clients will immediately unlock cross-selling opportunities. It will also lay down the foundations to build the capabilities to seize the Intelligent Operations strategic market opportunity. Intelligent Operations – Agentic AI creates a paradigm shift that opens a strategic opportunity The largest opportunity for global organizations to create value with Gen AI and Agentic AI lies in the fundamental redesign of their operations and business processes. It will attract a significant share of their AI investments as they seek to become AI-powered companies to lead their market. This is creating demand for a new type of business process services: Intelligent Operations. Intelligent Operations answers these business needs, providing a consulting-led approach to transform and operate horizontal and vertical business processes leveraging Gen AI and Agentic AI. It addresses clients’ goal of efficiency, speed and agility through process hyper-automation, while significantly improving business outcomes by combining data, AI and digital. AI technologies trigger a paradigm shift in delivering business process services: from labor-intensive services to being consulting-led and tech-driven. In parallel, client focus has shifted from efficiency gains toward end-to-end value creation and business outcomes, opening opportunities to add non-linear revenues (i.e. transaction-based, subscription-based or outcome-based models). This is creating a rapidly growing market opportunity. Combining the capabilities and scale required to lead in Intelligent Operations Both Capgemini and WNS are already pioneering Intelligent Operations. Capgemini with its consulting-led end-to-end transformation of processes, advanced AI tools and technology stacks, and BPS platforms, while WNS has developed a set of sector-specific AI-led solutions recently augmented by the acquisition of Kipi.ai7 to strengthen its data, analytics and AI capabilities. The combination of Capgemini and WNS will act as a catalyst to lead in Intelligent Operations providing the required scale and unique set of capabilities from Strategy & Transformation consulting, to horizontal and sector expertise, platform offerings to deep AI and technology capabilities. This combination will also leverage the significant investments made by Capgemini in AI through training, offers and its 25 strategic partnerships, including Microsoft, Google, AWS, Mistral AI and NVIDIA. The Group’s leadership is recognized by its clients, with over €900 million of Gen AI bookings in 2024, and by market analysts such as Forrester, IDC and ISG. This transaction will reinforce Capgemini as a business and transformation partner to those enterprises who want to become AI-powered businesses. Value creation Based on calendar year 2024 published information, the combined entities would have generated a revenue of €23.3 billion at a 13.6% operating margin6 in 2024. The Group expects accretion to normalized EPS, before synergies from the combination, of 4% in 2026. Capgemini expects revenue synergies run-rate of €100 million to €140 million by the end of 2027. Costs and operating model synergies are anticipated to reach an annual pretax run-rate of between €50 million and €70 million by the end of 2027. With the benefits of these synergies, the accretion on normalized earnings per share should reach 7% in 2027. Smooth integration WNS and Capgemini have a natural cultural fit and share common values that will facilitate a smooth integration of the teams, helped by the Group’s track record of successful integrations. Furthermore, the integration will be straightforward into Capgemini’s Global Business Services activities. Key transaction terms and timeline The contemplated transaction will be implemented by way of a Court-sanctioned scheme of arrangement under the laws of Jersey. The transaction has been unanimously approved by both Capgemini’s and WNS’ Boards of Directors. The transaction is subject to approval by the Royal Court of Jersey and WNS’ shareholders, as well as to receipt of customary regulatory approvals and other conditions. The closing of the transaction is expected to occur by the end of the year. Full details of the terms and conditions of the transaction are set out in the transaction agreement, which may be obtained, free of charge, on the SEC’s website (http://www.sec.gov) when available, and WNS’ website at https://www.WNS.com. Financing Capgemini has secured a bridge financing of €4.0 billion, covering the purchase of securities ($3.3 billion), as well as the gross debt and similar obligations8 of around $0.4 billion and the €0.8 billion Capgemini bond redeemed in June 2025. The Group plans to refinance the bridge with available cash for around €1.0 billion and the balance by debt issuance. Q2 and H1 2025 performance The Group expects Q2 2025 year-on-year growth at constant currency to be slightly better than the -0.4% reported in Q1 2025. The Group also expects for H1 2025 the operating margin to be stable year-on-year at 12.4%. Due to the nature and timing of this announcement, the actual Q2 and H1 2025 performance may slightly differ from the above-mentioned expectations. H1 2025 publication will take place as planned on July 30, 2025. Outlook Capgemini’s financial targets for 2025 do not take into account this transaction and are therefore unchanged: Revenue growth of -2.0% to +2.0% at constant currency;Operating margin of 13.3% to 13.5%;Organic free cash flow of around €1.9 billion. Conference call Aiman Ezzat, Chief Executive Officer, accompanied by Nive Bhagat, Chief Financial Officer, will comment on this announcement during two audio webcasts (in English only) to be held today: at 8.00 a.m. Paris time (CET) for "listen-only" participants: https://edge.media-server.com/mmc/p/npdpfjyy for investors and financial analysts who wish to take part in the Q&A session, please pre-register on the following link to receive the dial-in information and at 3.00 p.m. Paris time (CET) for "listen-only" participants: https://edge.media-server.com/mmc/p/y5nk6iup for investors and financial analysts who wish to take part in the Q&A session, please pre-register on the following link to receive the dial-in information Replays of both calls will be available, from the same links, shortly after the event and for a period of one year. All documents relating to this publication will be posted on the Capgemini investor website at https://investors.capgemini.com/en/. IMPORTANT NOTICE This announcement is for information purposes only and is not intended to and does not constitute or form part of, an offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities or the solicitation of any vote or approval in any jurisdiction in contravention of applicable law. In connection with the Transaction, WNS will provide to its shareholders and file with the U.S. Securities and Exchange Commission (the “SEC”) a circular relating to the Transaction (the “scheme document”) and may also file other documents with the SEC. The scheme document will contain the full terms and conditions of the Transaction, including details with respect to the WNS shareholder vote in respect of the Transaction and will be sent or otherwise disseminated to WNS’ shareholders and will contain important information about the Transaction and related matters. Any decision in respect of, or other response to, the Transaction should be made only on the basis of the information contained in the scheme document. SHAREHOLDERS OF WNS ARE ADVISED TO READ THE SCHEME DOCUMENT AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION. The scheme document and other relevant documents may be obtained, free of charge, on the SEC’s website (http://www.sec.gov), when available. WNS’ shareholders may obtain free copies of the scheme document once it is available from WNS by going to WNS’ website at https://www.wns.com. PARTICIPANTS IN THE SOLICITATION Capgemini, WNS and certain of their respective directors and officers may be deemed participants in the solicitation of proxies of WNS’ shareholders in connection with the Transaction. Additional information regarding the foregoing persons, including their direct and indirect interests, by security holdings or otherwise, will be set forth in the scheme document and other relevant documents to be filed with the SEC. WNS’ shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of WNS in WNS’ periodic reports filed with the SEC available on WNS’ website at https://www.wns.com, and regarding the directors and officers of Capgemini in Capgemini’s most recent Universal Registration Document (Document d’Enregistrement Universel) available on Capgemini’s website (https://www.capgemini.com/us-en/). FORWARD LOOKING STATEMENTS Certain information in this announcement, as well as oral statements made regarding the Transaction, and other information published by WNS, Capgemini or any member of the Capgemini Group contain statements which are, or may be deemed to be “forward-looking statements”, including, but not limited to, the acceleration of Capgemini and WNS’ growth and the value-additive nature of the Transaction for Capgemini shareholders. The words “anticipates”, “expects”, “believes”, “intends, “estimates”, “plans”, “projects”, “may”, “would”, “will”, “should”, “continue”, or the negative of these terms and similar expressions are intended to identify forward-looking statements. Such forward looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and on numerous assumptions regarding the business strategies and the environment in which Capgemini, any member of the Capgemini Group, including WNS and its subsidiaries following the Transaction (“Post-Transaction Group”) shall operate in the future and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. The forward looking statements contained in this announcement relate to Capgemini, any member of the Capgemini Group or the Post-Transaction Group’s future prospects, developments and business strategies, the expected timing and scope of the Transaction and other statements other than historical facts. For a discussion of some of the risks and important factors that could affect such forward-looking statements, please refer, without limitations, to the risks identified in Capgemini’s most recent Universal Registration Document (Document d’Enregistrement Universel) available on Capgemini’s website (https://www.capgemini.com/us-en/). Factors which could have a material adverse effect on the Company’s operations and future prospects include, but are not limited to, the following risks relating to the Transaction, including in respect of the satisfaction of closing conditions to the Transaction on a timely basis or at all, including the ability to obtain required regulatory approvals and the required scheme shareholder approval; unanticipated difficulties and/or expenditures relating to the Transaction and any related financing; uncertainties as to the timing of the Transaction; litigation relating to, or other challenges to, the Transaction; the impact of the Transaction on each company’s business operations (including the threatened or actual loss of employees, clients or suppliers); the inability to obtain, or delays in obtaining cost savings and synergies from the Transaction; incurrence of unexpected costs and expenses in connection with the Transaction; risks related to changes in the financial, equity and debt markets; and risks related to political, economic and market conditions. In addition, the risks to which WNS’ business is subject, including those risks described in WNS’ periodic reports filed with the SEC, could adversely affect the Transaction and, following the completion of the Transaction, the Company’s operations and future prospects. New risks and uncertainties emerge from time to time, and it is not possible for Capgemini and WNS to predict or assess the impact of every factor that may cause actual results to differ from those contained in any forward-looking statements. Specifically, statements of estimated cost savings and synergies relate to future actions and circumstances which, by their nature involve, risks, uncertainties and contingencies. As a result, the cost savings and synergies referred to may not be achieved, may be achieved later or sooner than estimated, or those achieved could be materially different from those estimated. Due to the scale of the Post-Transaction Group, there may be additional changes to the Post-Transaction Group’s operations. As a result, and given the fact that the changes relate to the future, the resulting cost synergies may be materially greater or less than those estimated. Forward-looking statements contained herein are only based upon currently available information and speak only as of the date of this announcement, and Capgemini expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Capgemini’s expectations with regard thereto or change in events, conditions or circumstances on which any statement is based. Past performance is not a reliable indicator of future results and should not be relied upon for any reason. The anticipated financial impact of the acquisition of WNS and any references to future financial performance should not be viewed as management guidance. Actual results may differ from the statements set forth herein and such differences may be material. ABOUT CAPGEMINI Capgemini is a global business and technology transformation partner, helping organizations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fueled by its market leading capabilities in AI, generative AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2024 global revenues of €22.1 billion. Get the Future You Want | www.capgemini.com ABOUT WNS WNS is a digital-led business transformation and services company. WNS combines deep domain expertise with talent, technology, and AI to co-create innovative solutions for over 600 clients across various industries. WNS delivers an entire spectrum of solutions including industry-specific offerings, customer experience services, finance and accounting, human resources, procurement, and research and analytics to re-imagine the digital future of businesses. As of March 31, 2025, WNS had 64,505 professionals across 64 delivery centers worldwide including facilities in Canada, China, Costa Rica, India, Malaysia, the Philippines, Poland, Romania, South Africa, Sri Lanka, Turkey, the United Kingdom, and the United States. For more information, visit www.wns.com 1 Volume-weighted average2 Net financial debt of WNS was negligible as at March 31, 20253 Clients of WNS based on public domain information4 WNS fiscal year ends March 31. Last 3 fiscal years end March 2025.5 Revenue represents revenue less repair payments6 WNS “Adjusted operating profit” restated to expense amortization of intangible assets (software) above operating margin to conform to Capgemini’s definition of operating margin.7 See https://ir.wns.com/news-releases/news-release-details/wns-acquires-kipiai-expand-data-analytics-ai-capabilities 8 Including considerations to be paid in connection with Restricted Share Units Attachment Capgemini_-_2025-07-07_-_Capgemini_to_acquire_WNS_to_create_a_global_leader_in_Intelligent_Operations
Massive Global Crypto Fraud Network Dismantled in Spain, Over 5,000 Victims Targeted - TechBullion
Spanish authorities, with support from Europol and international law enforcement, recently dismantled a global cryptocurrency fraud network that defrauded over 5,000 victims. The operation led to five arrests and uncovered a scheme that laundered more than €460 million ($542 million) through fake crypto investment deals. The criminals, operating out of Spain, used a network of […]
Fintech AI: Reshaping the startup landscape in Europe - TechBullion
Fintech AI solutions are democratizing financial services across the globe. Let’s begin by understanding the concept of fintech. “Fintech” is a word derived from joining two words, that is, “finance” and “technology,” meaning how technology and finance collaborate to provide technological solutions in the finance sector. Fintech provides digital tools to improve and automate financial […]
China Expresses Concern To EU Over Russia's Potential Defeat In Ukraine Conflict Amid Fears That Trump Would Do 'This': Report - Benzinga
Chinese Foreign Minister Wang Yi has reportedly expressed concern to the European Union about a potential Russian defeat in the ongoing Ukraine conflict, contradicting China's public stance on the matter.